Matthew Majewski

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.